DossierENTITY

KRAS-driven tumors

Coverage of KRAS-driven tumors in the Nexus archive.

Earliest in view: Jun 8 · 13:40 UTCMost recent: Jun 8 · 13:40 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 8 · 13:40 UTCQUARTZ
Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion
Johnson & Johnson is acquiring cancer drug biotech Firefly Bio for $1 billion. The deal focuses on KRAS-driven tumors, which have limited treatment options and survival measured in months.